Clinical Trial Detail

NCT ID NCT02768701
Title Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center

triple-receptor negative breast cancer


Cyclophosphamide + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.